Price hearing cheat sheet: CEOs prep for grilling, history repeats itself and more
February 26, 2019
By Neozene

The nation’s capital is abuzz as Big Pharma CEOs rehearse their testimony for Tuesday’s big drug-pricing hearing. What to expect? High political theater, for one thing, as Republicans and Democrats both take their shots. But don’t dismiss the event as mere grandstanding, analysts say. Senators on the dais have introduced pricing bills and launched investigations, and the Trump administration seems willing to participate in a crackdown. Plus, every D.C. media outlet will be covering it—zeroing in on the most dramatic exchanges, of course—and those TV news feeds and mainstream media headlines

Read More

Preventing Unnecessary Exposure to Opioids After Surgery
February 19, 2019
By Neozene

It’s nearly impossible to pick up a newspaper or scroll through Twitter without coming across a story about the misuse of and addiction to opioids.  These include prescription pain relievers, heroin, and synthetic opioids such as fentanyl. With 130 people dying of an overdose every day, it has become our country’s greatest health crisis since the AIDS epidemic of the 80s and 90s…an epidemic that can affect anyone regardless of age, culture, education or socio-economic status. More than 650,000 opioid prescriptions are dispensed on an average day, according to the

Read More

J&J’s Nasal Antidepressant Heads for FDA Panel
February 12, 2019
By Neozene

Johnson & Johnson’s new antidepressant esketamine comes in front of an FDA advisory committee tomorrow, hoping to end a drought in novel therapies for the disorder. There has been a lot of debate about the likely outcome of the meeting given that not all of J&J’s studies support the intranasally administered drug, but analysts at Credit Suisse think that the FDA is “supportive of approval” based on published briefing documents. If approved by the FDA, esketamine would become one of the first new approaches to treat refractory major depressive disorder (MDD)

Read More